GSK Completes $950M Acquisition of 35Pharma Inc.
GlaxoSmithKline (GSK) has completed its acquisition of Canadian clinical-stage biopharmaceutical company 35Pharma Inc. for $950 million, gaining control over a drug pipeline including HS235 for pulmonary hypertension and showing potential in metabolic benefits. Additionally, GSK reported promising early results from its experimental cancer medicine Mo-rez.
Tickers: $GSK
Topics: Biotech Acquisition Drug Pipeline Expansion Pharmaceuticals